Glucosa Viaflex Baxter (Glucose Monohydrate)

Glucosa Viaflex Baxter is indicated for several clinical situations where rapid carbohydrate delivery or fluid replacement is required.

• Management of acute hypoglycemia when oral glucose is not feasible.
• Supplementation of caloric intake in patients receiving total parenteral nutrition.
• Maintenance of intravascular volume and electrolyte balance during surgery or critical illness.
• Support for patients with prolonged fasting or inability to ingest nutrients orally.
• Adjunctive therapy for dehydration combined with electrolyte disturbances.

The safety profile of Glucosa Viaflex Baxter reflects the expected physiological response to intravenous glucose administration.

Common

• Transient hyperglycemia
• Mild nausea or vomiting
• Local irritation at the infusion site
• Temporary increase in serum osmolality
• Mild electrolyte shifts (e.g., sodium, potassium)

Serious

• Severe hyperglycemia leading to osmotic diuresis
• Hypotension from rapid infusion
• Allergic or anaphylactic reaction to the solution
• Hyperosmolar hyperglycemic state in susceptible patients
• Metabolic acidosis secondary to over‑infusion

Clinicians should observe specific precautions when prescribing Glucosa Viaflex Baxter to ensure patient safety and therapeutic effectiveness.

• Verify blood glucose level before and after infusion to avoid extreme fluctuations.
• Adjust infusion rate in patients with renal or cardiac impairment to prevent fluid overload.
• Use caution in individuals with known hypersensitivity to glucose solutions or excipients.
• Monitor electrolytes, especially sodium and potassium, during prolonged administration.
• Avoid use in patients with uncontrolled diabetes mellitus without close glucose monitoring.
• Ensure proper aseptic technique to prevent catheter‑related infections.

Glucosa Viaflex Baxter may interact with other medications or clinical conditions; awareness of these interactions helps guide safe use.

Avoid

• Concurrent administration of high‑dose insulin without glucose monitoring.
• Co‑infusion with hypertonic saline solutions that may exacerbate hyperosmolar states.
• Use with drugs that significantly lower blood glucose (e.g., sulfonylureas) without adjusting doses.

Use with caution

• Combination with diuretics that affect fluid balance; monitor volume status.
• Concurrent use of potassium‑sparing agents; watch for hyperkalemia.
• Administration alongside catecholamines that can alter glucose metabolism; observe glucose trends.